Charles River's Parkinson's disease model platform uses manipulation of the unilateral 6-hydroxydopamine (6-OHDA) model in order to take into account both acute and symptomatic effects of Parkinson's disease. In addition, we have, as the product of its own in-house validations, a MPTP model available.
Models for Parkinson's Disease
- 6-OHDA Medial Forebrain Bundle Model
- 6-OHDA Striatal Model
- MPTP Model
Example Study Paradigm of 6-OHDA Striatal Model

Click here to see a diagram outlining an example study paradigm using our 6-OHDA Striatal model.
Data

Quantification of tyrosine hydroxylase (TH) postivie neurons in substantia nigra (SNc) at 14 days after MPTP challenge

Quantification of Dopamine (DA) content in striatum by HPLC at14 days after MPTP challenge

Amphetamine-Induced net rotational activity in 6-OHDA median forebrain bundle lesioned rats over time

Tyrosine hydroxylase postive neurons in substantia nigra (SNc)
For more information about our models used to research Parkinson’s disease, please contact us at askcharlesriver@crl.com.
Charles River also offers an in vitro Parkinson’s disease model. For more information, click here.